Skip to main content
. 2016 Oct 28;5(12):e1250992. doi: 10.1080/2162402X.2016.1250992

Figure 2.

Figure 2.

The clinical outcomes between the IL-2 and control arms. (A) Relapse, (B) non-relapse mortality (NRM), (C) minimal residual disease (MRD), (D) moderate-to-severe chronic GVHD, (E) overall survival (OS) and (F) GVHD-free and relapse-free survival (GPFS). Patient cohorts: IL-2 group (n = 43) and control group (n = 47).